250 likes | 537 Views
Immunization. Abdul Ghaffar Microbiology and Immunology. Milestones in immunization. 3000BC Evidence of sniffing powdered small pox crust in Egypt. 1500BC Turks introduce variolation. 1700AD Introduction of variolation in England and later in the US. 2000BC
E N D
Immunization Abdul Ghaffar Microbiology and Immunology
Milestones in immunization • 3000BC • Evidence of sniffing powdered small pox crust in Egypt • 1500BC • Turks introduce variolation • 1700AD • Introduction of variolation in England and later in the US • 2000BC • Sniffing of small pox crust in China
Introduction of variolation The wife of the British Ambassador in Turkey, in March 1717 wrote, following the variolation of her son, to a friend in England: “The small pox, so fatal, so general amongst us, is entirely harmless here by the invention of ingrafting….I am patriot enough to bring this invention into fashion in England.
Milestones in immunization • 1780AD • Edward Jenner discovers small pox vaccine
Edward Jenner Discovery of small pox vaccine
Modern era of the vaccine • 1885 • Rabies vaccine (Pasteur) • 1934 • Pertussis • 1955 • Salk polio • 1920s • Diphtheria and Tetanus
Modern era of the vaccine • 1960s • Mumps measles and rubella virus • Sabin polio • 1985 • Haemophilus • 1990s • Hepatitis and varicella
Pre- & post-vaccine incidence of common preventable diseases
Acquired Natural resistance Passive Active Artificial Artificial Natural Natural Different modes of acquiring immunity Immunity
Natural Artificial Passive Immunity Placental transfer of IgG Antibodies or immunoglobulins Colostral transfer of IgA Immune cells
disease diphtheria, tetanus human, horse antibody source indication human vericella zoster horse gas gangrene, botulism, snake bite, scorpion sting prophylaxis, therapy immunodeficiencies post-exposure post-exposure human human rabies, prophylaxis hypogamma-globulinemia Passive Immunization
Disadvantages Advantages Advantages and Disadvantages of Passive Immunization no long term protection serum sickness immediate protection risk of hepatitis and Aids graft vs. host disease (cell graft only)
Artificial Natural Active Immunization Attenuated organisms killed organisms exposure to sub-clinical infections sub-cellular fragments toxins others
Live Attenuated Vaccines • hepatitis A • not required in SC • polio* • not used in std. schedule • yellow fever • Military and travelers measles, mumps & rubella • Varicella zoster • children with no history of chicken pox • tuberculosis • not used in this country
Killed Whole-Organism Vaccines polio • Q fever • population at risk • influenza • elderly and at risk • typhoid, cholera, plague • epidemics and travelers • pertussis • replaced by the acellular vaccine • rabies • post exposure
Microbial Fragment Vaccines • Bordetella. Pertussis • virulence factor protein • Haemophilus influenzae B • protein conjugated polysaccharide • Streptococcus pneumoniae • Polysaccharide mixture • Neisseria meningitidis • polysaccharide
Microbial Fragment Vaccines • Clostridium tetani (tetanus) • inactivated toxin (toxoid) • Corynebacterium diphtheriae • inactivated toxin (toxoid) • Vibrio cholerae • toxin subunits • Hepatitis B virus • cloned in yeast
Toxoid chemical modification toxin moiety antigenic determinants Modification of Toxin to Toxoid Toxin
Future Vaccines • anti-Idiotype Vaccine DNA Immuno-dominant peptide
Event Frequency • local • redness, swelling, pain 1 in 2-3 doses • systemic: Mild/moderate • fever, drowsiness, fretfulness vomiting • anorexia 1 in 2-3 doses 1 in 5-15 doses • systemic: more serious • persistent crying, fever • collapse, convulsions • acute encephalopathy • permanent neurological deficit 1 in 100-300 doses 1 in 1750 doses 1 in 100,000 doses 1 in 300,000 doses Adverse Events OccurringWithin 48 Hours DTP of Vaccination